A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency, Agammaglobulinemia and Hypogammaglobulinemia, sponsored by Kedrion S.p.A.. Completed at 15 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 18 in phase 3, and was the 17th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
Kedrion S.p.A. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Kedrion S.p.A. has 3 studies filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).
People with primary immunodeficiency diseases (PID) have a defective immune system and experience recurrent protozoal, bacterial, fungal and viral infections. Antibody deficiencies make up the largest group of PIDs.
The standard care for patients with PID is replacement immunoglobulin (a class of antibodies) solution. Prophylactic treatment with intravenous immunoglobulin (IVIG) solution has been shown to increase the time free from serious infection.
Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution. Kedrion IVIG 10% will be given by IV infusion to all study participants. The data collected will help determine whether Kedrion IVIG 10% is suitable for treating PID subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Kedrion IVIG 10% treatment.
Biological: Kedrion IVIG 10%
Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.
The incidence of acute serious bacterial infections, e.g. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis, meeting EMA and FDA criteria.
Time frame: 13 months
Infections Other Than Acute, Serious Bacterial Infections (ASBIs) in the Total ITT Population.
Time frame: 13 months
Days Out of Work/School/Daycare Due to Infection in the Total ITT Population.
Time frame: 13 months
Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.
Time frame: 13 months
Days on Therapeutic Antibiotics in the Total ITT Population.
Time frame: 13 months
Days of Unscheduled Visits to Physicians in the Total ITT Population.
Time frame: 13 months
Number of Hospitalizations Due to Infection in ITT Population.
Time frame: 13 months
Days of Hospitalization Due to Infection in the Total ITT Population.
Time frame: 13 months
Yearly Hospitalization Rate Due to Infection in the Total ITT Population.
Time frame: 13 months
Yearly Hospitalization Duration Due to Infection in the Total ITT Population.
Time frame: 13 months
Distribution of All-cause Hospitalizations in the Total ITT Population.
Time frame: 13 months
Duration of All-cause Hospitalizations
Time frame: 13 months
Distribution of Fever Episodes in the Total ITT Population.
Time frame: 13 months
Duration of Fever Episodes
Time frame: 13 months
IgG Trough Levels at Steady State in the Total ITT Population.
Time frame: 13 months
| Milestone | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Started | 45 |
| Completed | 44 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The incidence of acute serious bacterial infections, e.g. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis, meeting EMA and FDA criteria.
| ASBI's/person-year | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Incidence of Acute, Serious Bacterial Infections in the Total ITT Population. | 0.04 (0.00 to 0.11) |
| infect./subject's study duration (years) | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Upper respiratory tract infection | 0.42 |
| Sinusitis | 0.48 |
| Viral upper respiratory tract infection | 0.15 |
| Bronchitis | 0.11 |
| Nasopharyngitis | 0.11 |
| Rhinitis | 0.11 |
| Acute sinusitis | 0.15 |
| Gastroenteritis viral | 0.09 |
| Herpes zoster | 0.11 |
| Urinary tract infection | 0.11 |
| days | Kedrion IVIG 10% 21 & 28 Days Treatment Schedule |
|---|---|
| Days Out of Work/School/Daycare Due to Infection in the Total ITT Population. | 2.8 ± 6.56 |
| days | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population. | 3.4 ± 6.53 |
| days | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Days on Therapeutic Antibiotics in the Total ITT Population. | 23.3 ± 33.77 |
| days | Kedrion IVIG 10% 21 and 28 Days Infusion Schedule |
|---|---|
| Days of Unscheduled Visits to Physicians in the Total ITT Population. | 0.9 ± 1.14 |
| Participants | Kedrion IVIG 10% 21 & 28 Days Treatment Schedule |
|---|---|
| 0 hospitalizations | 42 |
| 1 hospitalization | 2 |
| 2 hospitalizations | 1 |
| ≥ 3 hospitalizations | 0 |
| days | Kedrion IVIG 10% 21 & 28 Days Treatments Schedule |
|---|---|
| Days of Hospitalization Due to Infection in the Total ITT Population. | 0.6 ± 2.21 |
| hospitalizations per year | Kedrion IVIG 10% 21 & 28 Days Treatments Schedule |
|---|---|
| Yearly Hospitalization Rate Due to Infection in the Total ITT Population. | 0.11 ± 0.436 |
| days | Kedrion IVIG 10% 21 & 28 Days Treatments Schedule |
|---|---|
| Yearly Hospitalization Duration Due to Infection in the Total ITT Population. | 0.55 ± 2.196 |
| Participants | Kedrion IVIG 10% 21 and 28 Days Treatment Schedule |
|---|---|
| 0 hospitalizations | 41 |
| 1 hospitalization | 1 |
| 2 hospitalizations | 2 |
| 3 hospitalizations | 1 |
| ≥ 4 hospitalizations | 0 |
| days | Kedrion IVIG 10% 21 and 28 Days Treatment Schedule |
|---|---|
| Duration of All-cause Hospitalizations | 17.8 ± 12.07 |
| Participants | Kedrion IVIG 10% 21 and 28 Days Treatment Schedule |
|---|---|
| 0 fever episodes | 34 |
| 1 fever episode | 6 |
| 2 fever episodes | 2 |
| 3 fever episodes | 1 |
| 4 fever episodes | 1 |
| 5 fever episodes | 1 |
| days | Kedrion IVIG 10% 21 and 28 Days Treatment Schedule |
|---|---|
| Duration of Fever Episodes | 6.5 ± 4.87 |
| mg/dL | Kedrion IVIG 10% 21 and 28 Days Treatment Schedule |
|---|---|
| IgG Trough Levels at Steady State in the Total ITT Population. | 888 ± 197 |
Collected over 13 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kedrion IVIG 10% | — | 4/45 (8.9%) | 44/45 (97.8%) |
| Event | Kedrion IVIG 10% |
|---|---|
| Bacterial pneumoniaInfections and infestations | 1/45 |
| Herpes zosterInfections and infestations | 1/45 |
| Infective exacerbation of bronchiectasisInfections and infestations | 1/45 |
| Bipolar disorderPsychiatric disorders | 1/45 |
| DiarrhoeaGastrointestinal disorders | 1/45 |
| Humerus FractureInjury, poisoning and procedural complications | 1/45 |
| PneumoniaInfections and infestations | 1/45 |
| Event | Kedrion IVIG 10% |
|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 13/45 |
| HeadacheNervous system disorders | 12/45 |
| InvestigationsInvestigations | 12/45 |
| SinusitisInfections and infestations | 11/45 |
| PyrexiaGeneral disorders | 11/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/45 |
| FatigueGeneral disorders | 8/45 |
| DiarrhoeaGastrointestinal disorders | 8/45 |
| Back PainMusculoskeletal and connective tissue disorders | 7/45 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 6/45 |
| Age, Categorical(Participants) | Kedrion IVIG 10% 21 and 28 Day Infusion Schedule |
|---|---|
| <=18 years | 9 |
| Between 18 and 65 years | 27 |
| >=65 years | 9 |
| Age, Continuous(years) | Kedrion IVIG 10% 21 and 28 Day Infusion Schedule |
|---|---|
| Mean | 39.9 ± 20.7 |
| Sex: Female, Male(Participants) | Kedrion IVIG 10% 21 and 28 Day Infusion Schedule |
|---|---|
| Female | 13 |
| Male | 32 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2012 to primary completion in Aug 2014, 21 months.
Results were first posted in Feb 2021, 6 years 5 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →
Kedrion S.p.A.